Evidence-based approach to challenging issues in the management of invasive aspergillosis

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Singh, N ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antifungal therapy; Aspergillus; Fungal infections; Transplants

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN A; CYTOCHROME P450; GALACTOMANNAN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 4; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; ASPERGILLOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HOST RESISTANCE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE ASPERGILLOSIS; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; REVIEW; SALVAGE THERAPY; TH1 CELL; TH17 CELL; TH2 CELL; CASE MANAGEMENT;

ASPERGILLUS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 67651103058     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802552598     Document Type: Review

References (54)

1. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005; 41: 52-59.
2. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: Report of 9 cases and review of the literature. Medicine 1996; 75: 142-156.
3. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
4. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
5. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive Aspergillus Cancer 2006; 107: 2888-2897.
6. Mattner F, Chaberny IF, Weibrodt H, et al. Surveillance of invasive mold infections in lung transplant recipients: Effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses 2005; 48: 51-55.
7. Herbrecht R, Denning D, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
8. Husain S, Paterson DL, Studer SM, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 12: 2765-2773.
9. Sole A, Morant P, Salavert M, et al. Aspergillus in lung transplant recipients: Risk factors and outcome. Clin Microbiol Infect 2005; 11: 359-365.
10. Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180: 1957-1968.
11. Roilides E, Dignani MC, Anaissie EJ, et al. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 1998; 36: 12-25.
12. Grazziutti ML, Rex JH, Cowart RE, et al. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis 1997; 176: 1579-1583.
13. Roilides E, Dimitriadou-georgiadou A, Sein T, et al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998; 66: 5999-6003.
14. Clemons KV, Stevens DA. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir Infect 2001; 16: 60-66.
15. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individual and patients with hematologic malignancies. Blood 2003; 100: 4521-4528.
16. Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695-2706.
17. Singh N, Lortholary O, Alexander BD, et al. An 'immune reconstitution syndrome'-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis 2005; 40: 1756-1761.
18. Cheng VCC, Yuen K-Y, Chan W-M, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30: 882-892.
19. Miceli M, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112-120.
20. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: 395-401.
21. Summers SA, Dorling A, Boyle JJ, et al. Cure of disseminated cryptococcal infection in a renal allograft recipient after the addition of γ-interferon to antifungal therapy. Am J Transplant 2005; 5 2067-2069.
22. Lanternier F, Chandesris M, Poirée S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 12: 2826-2828.
23. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
24. Groll A, Renz S, Gerein V. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF). Mycoses 1992; 35: 67-75.
25. Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: Rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999; 29: 453-457.
26. Woods G, Miceli M, Grazziutti M, et al. Serum Apergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer 2007; 110: 830-834.
27. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-241.
28. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitide and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744.
29. Isoherranen N, Kunze KL, Allen K, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32 1121-1131.
30. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation; a report of two cases. Transplant Proc 2004; 36: 2708-2709.
31. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 552-559.
32. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 6: 825-834.
33. Verweij P, Meis J. Microbiological diagnosis of invasive fungal infectious transplant recipients. Transplant Infect Dis 2000; 2 80-87.
34. Sable CA, Nguyen BY, Chodakewitz JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25-30.
35. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
36. Anttila VJ, Piilonen A, Valtonen M. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. Scand J Infect Dis 2003; 35: 893-894.
37. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34: 328-332.
38. Vazquez J. Anidulafungin: A new echinocandin with a novel profile. Clin Ther 2005; 27: 657-673.
39. Dowell J, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 461-470.
40. Dowell J, Schranz J, Baruch A, et al. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 45: 1373-1382.
41. Jospeh J, Jain R, Danziger L. Micafungin: A new echinocandin antifungal. Pharmacotherapy 2007; 27: 53-67.
42. Herbert M, Blough D, Townsend R, et al. Concomitant cyclosporine and micafungin pharmacokinetcs in healthy volunteers. J Clin Pharmacol 2005; 45: 1018-1024.
43. Cahanrasekar P, Sobel J. Reviews of anti-infective agents. Micafungin: A new echinocandin. Clin Infect Dis 2006; 45: 883-893.
44. Odom A, Muir S, Lim E, et al. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 1997; 16: 2576-2589.
45. Cruz MC, Goldstein AL, Blankenship JR, et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO Journal 2002; 21: 546-559.
46. Steinbach W, Cramer RA, Perfect BZ, et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryotic Cell 2006; 5: 1091-1103.
47. Steinbach W, Cramer RA, Perfect BZ, et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemotherap 2007; 81: 2979-2981.
48. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive apergillosis. Clin Infect Dis 2004; 39: 797-802.
49. Kontoyiannis DPR, Lewis RE, Lionakis MS, et al. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diag Microbiol Infect Dis 2003; 47: 415-419.
50. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B standard dose in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocompromised patients: Randomized pilot study (combistrat trial). Cancer 2006; 110: 2740-2746.
51. Singh N, Limaye A, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter observational trial. Transplantation 2006; 81: 320-326.
52. Singh N, Wagener MM, Cacciarelli TV, et al. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426-431.
53. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
54. Muñoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections; should a combination of antifungal drugs be used? Curr Opin Immunol 2006; 19: 365-370.